Alveolar Bone Grafting in Association With Polyostotic Fibrous Dysplasia and Bisphosphonate-Induced Abnormal Bone Turnover in a Bilateral Cleft Lip and Palate Patient: A Case Report

Kodama, Yasumitsu; Ogose, Akira; Oguri, Yoshimitsu; Ubaidus, Sobhan; Iizuka, Tetsuya; Takagi, Ritsuo

doi:10.1016/j.joms.2012.05.015

Cited by 7 publications

(7 citation statements)

References 22 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first and second right mandibular molars were hemisected. The distal roots were orthodontically extruded for several weeks and afterwards extracted [10]. …”

Section: Resultsmentioning

confidence: 99%

Current state of orthodontic patients under Bisphosphonate therapy

2013

View full text Add to dashboard Cite

BackgroundBisphosphonates are a common medication for the prevention and therapy of osteoporosis, but are also applied for tumor diseases. They affect bone metabolism, and therefore also orthodontic treatments, but how it does has yet not been definitively clarified. Therefore, the aim of this research was to evaluate and demonstrate the reported effects and the current state of scientific research regarding orthodontic treatment and bisphosphonate medication exclusively in humans.Material and methodsA systematic research of the literature for selected keywords in the Medline database (Pubmed) as well as a manual search was conducted. The following search terms were used: ‘Bisphosphonate’ in combination with: orthodontic, orthodontic treatment, tooth movement.FindingsTo date, only nine reported patients (case reports/series) and one original article (retrospective cohort study) regarding orthodontic treatment under bisphosphonate medication in humans have been published. Decelerated tooth movement with increased side effects (especially in high-risk patients) and longer treatment duration was reported in some articles. Patients with initial spacing or extraction cases had a higher risk of incomplete space closure and poor root parallelism.ConclusionsOrthodontic tooth movement under bisphosphonate medication is possible, especially in low-risk patients (low dose and short period of intake). But the treatment is still not predictable, especially in high-risk patients. Therefore, the altered bone metabolism and higher extent of side effects should be considered in treatment planning, especially in extraction cases or high-risk patients. Regardless, longer treatment duration, decelerated tooth movement, and more side effects, e.g., incomplete space closure and poor root parallelism, should be expected, especially in extraction cases or space closure.

show abstract

“…The first and second right mandibular molars were hemisected. The distal roots were orthodontically extruded for several weeks and afterwards extracted [10]. …”

Section: Resultsmentioning

confidence: 99%

Current state of orthodontic patients under Bisphosphonate therapy

2013

View full text Add to dashboard Cite

show abstract

“…Orthodontic treatment of patients on BP medication has been critically assessed in several reviews [ 47 ], [ 59 ], [ 60 ]. There is limited clinical data on the influence of BPs on orthodontic therapy in patients on which recommendations can be based [ 46 ], [ 59 ], [ 61 ], [ 62 ], [ 63 ], [ 64 ], [ 65 ], [ 66 ], [ 67 ]. In general, it is pointed out that although orthodontic treatment can be successfully performed with respect to largely atraumatic procedures, treatment time can sometimes be considerably prolonged, the amount of force applied for tooth movement must be increased, and the goal of tooth movement may not be achieved [ 47 ], [ 59 ], [ 60 ].…”

Section: Discussionmentioning

confidence: 99%

“…In this additional case, several findings were registered: hypermineralization at the extraction site of teeth, sclerotic bone, widened periodontal gaps, decelerated tooth movement, and continuation of side effects despite stopping medication [ 59 ]. Most patients (n=6) in the review article had been treated with BP medication for osteoporosis, but generalized bone disease (fibrous dysplasia) [ 64 ], metabolic diseases (Addison’s disease), and malignancy with bone manifestations were also among the indications for drug-induced inhibition of osteoclasts [ 62 ].…”

Section: Discussionmentioning

confidence: 99%

The effect of bisphosphonate medication on orthodontics and orthognathic surgery in patients with osteogenesis imperfecta

Friedrich

Scheuer²,

Höltje

2019

GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW; 8:Doc06

View full text Add to dashboard Cite

“…Since then, a number of publications reported variable beneficial effects of different bisphosphonates on pain, bone turnover markers and radiological features of FD/MAS lesions largely in adults and children with polyostotic FD/MAS. These publications include 18 case reports , 20 observational case series and a single randomized controlled study (RCT) using oral alendronate .…”

Section: Antiresorptivesmentioning

confidence: 99%

“…Case reports were predominantly on women (11/18), seven on children and six reporting the effects of treatment with zoledronate and pamidronate in patients with isolated craniofacial FD (CFD) . Positive outcome of treatment in the form of decreased pain was reported in all patients, associated by a concomitant normalization in bone turnover markers in six of the 17 patients in whom these markers were measured before and after treatment .…”

Section: Antiresorptivesmentioning

confidence: 99%

Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone

Rotman

Hamdy

Appelman‐Dijkstra

2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

Fibrous dysplasia (FD) is a genetic, noninheritable rare bone disease caused by a postzygotic activating mutation of the α subunit of the stimulatory G‐protein causing increased abnormal bone formation leading to pain, deformity and fractures. To date, no cure has been identified for FD/McCune–Albright syndrome (MAS) and treatment is symptomatic and aimed at decreasing pain and/or local bone turnover. Various drugs have been used to achieve clinical improvement in FD/MAS patients including bisphosphonates and denosumab, however further translational studies are also warranted to address unresolved pathophysiological issues and explore novel pharmacological targets for the management of FD/MAS. In this article, we review literature on the medical treatment of FD/MAS, discuss the unresolved pathophysiological issues and explore novel pharmacological targets for the management of FD/MAS.

show abstract

Alveolar Bone Grafting in Association With Polyostotic Fibrous Dysplasia and Bisphosphonate-Induced Abnormal Bone Turnover in a Bilateral Cleft Lip and Palate Patient: A Case Report

Cited by 7 publications

References 22 publications

Current state of orthodontic patients under Bisphosphonate therapy

Current state of orthodontic patients under Bisphosphonate therapy

The effect of bisphosphonate medication on orthodontics and orthognathic surgery in patients with osteogenesis imperfecta

Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone

Contact Info

Product

Resources

About